Clinical Trial Update: Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients [Phase 3]

View source ↗

Summary

Phase 3 multinational trial compares isatuximab with pomalidomide and dexamethasone versus pomalidomide and dexamethasone in relapsed or refractory multiple mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Isatuximab (isatuximab)
• Pomalyst (pomalidomide)

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2019-12-06